Soo-Ryum (Stew) Yang MD
@sooryumyang
Followers
498
Following
483
Media
13
Statuses
465
molecular & thoracic pathologist @mskcancercenter alum: @vumedicine @stanford @ucsf 🇺🇸🇰🇷🏳️🌈
New York & San Francisco
Joined November 2013
Please check out our latest review on rare lung cancer subtypes! @MSKPathology #mskimpact #mskfusion #mskaccess.
In a Review now published online, Guilherme Harada, Soo-Ryum Yang, @emilianoCocco2 and @alexdrilon discuss some molecular subtypes of #lungcancer that, despite occurring in <5% of patients with this cancer type, affect a considerable number of individuals
1
3
16
RT @lungoncdoc: What should young patients ask about their lung cancer pathology? . Dr. @sooryumyang breaks it down at @cure_today’s FIRST….
0
6
0
RT @lungoncdoc: Final day of #TTLC25!. ☕ Kick off your morning in the Mariner’s Ballroom as we dive into all things HER2+ NSCLC!!. @Medscap….
0
4
0
RT @lungoncdoc: Join @tnewsomdavis, @sooryumyang, & me for @MedscapeOnc’s Live Event! . 🎙️Educating, Empowering, & Engaging: A Focus on HER….
0
5
0
RT @IHC_guy: Please join us tomorrow morning, November 13 at 11 am ET for the @ISIMMweb monthly webinar. @sooryumyang from @MSKPathology i….
0
24
0
Please vote for our case!! You know it’s a good case when you have a multidisciplinary collaboration between MD Anderson and Memorial Sloan Kettering! 🙏🏻🫁🧬💊🔬.
Lots of excitement with the @IASLC educational Amazing Case Race! . Be sure to vote for your favorite one! #WCLC24 @sooryumyang @ChristianRolfo @RManochakian .
1
3
13
Please join me and Dr. Jamie Chaft as we explore the latest updates in actionable biomarkers in early-stage NSCLC this Monday, September 9, 2024 at 12:30 PM PDT (Room: 33ABC) #WCLC24
0
7
29
RT @lungoncdoc: (Unofficial) @IASLC Academy meet up is already happening! . So grateful for these two physician friends of mine! @sooryumya….
0
2
0
RT @sooryumyang: Please join me and Dr. Jonathan Goldman as we discuss important updates in EGFR biomarker testing and treatment for advanc….
0
3
0
RT @mkbaine: Application are open for the ‘26-‘27 #Cytopathology fellowship @MSKPathology. We offer high volume exposure to diverse spec….
0
4
0
RT @POTUS: Today, we celebrate the anniversary of the monumental marriage equality ruling of Obergefell v. Hodges. This case moved our cou….
0
6K
0
Please join me and Dr. Jonathan Goldman as we discuss important updates in EGFR biomarker testing and treatment for advanced and early-stage NSCLC. @EGFRResisters @TheUSCAP.
🧬 Dive into the clinical implications of EGFR mutations in NSCLC. Learn to evaluate mutational status and use it to guide therapy plans. Enhance your diagnostic and treatment decisions through effective communication! 🎯 Join @sooryumyang & other experts:
0
3
8
RT @VivekSubbiah: 🚨It's Friday and time for another FDA approval! .👉FDA grants accelerated approval to adagrasib + cetuximab for KRAS G12C….
0
4
0
RT @EmpireStateBldg: Lighting tonight in partnership with @mskcancercenter in Honor of MSK’s 140th Anniversary and the ‘NYC for MSK’ Campai….
0
75
0
RT @HHorinouchi: 🩸#ASCO24 Minimal Residual Disease #MRD Series🔥.📢#8078 #LCSM.🎙️Dr. James M. Isbell @max_diehn.🧬SNV-based CAPP-Seq.🧬Phased v….
0
6
0
RT @fred_hirsch: We need more prospective bio marker studies, particularly to study the role of ct DNA MRD. Tic Tac Toe study is interestin….
0
6
0
RT @esinghimd: 1/ 🔥Our 🆕 @ClinicalLung Brief Report on 1L testing & management in mNSCLC is out! With multiple frontline treatments, it's a….
0
11
0
Thank you to our patients and those who led & contributed to this study @MLadanyi @JL_Sauter @michael_offin @ChrisFebres @jamalbenhamida @MSKPathology @IASLC @PulmPathSoc @curemeso.
0
1
2
Given the enrichment in biphasic histology & TILS, along with our anecdotal IO response data and PrE0505 trial data, these findings suggest that IO may represents an effective therapeutic option for this biomarker-selected cohort.
1
1
3